Atrium Therapeutics, Inc.
NASDAQ:RNABiotechnology
+$0.16 today
- Market cap
- $143.23M
- Beta
- 0.42
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$3.78
Volume 0.22M
Average 0.35M
RNA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Atrium Therapeutics, Inc.NASDAQ: RNA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow of $301.51M in Q1 FY2026
Q1 FY2026 financing cash flow was $301.51M.
Context
- Financing cash flow amounted to 228.7% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 42.57M USD
- Year-over-year change
- —
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 42.57M | — |
Financing Cash Flow vs competitors
How RNA compares with its peers on the latest reported figures
No competitor Financing Cash Flow figures are available to compare.
Cash Flow Statement
Atrium Therapeutics, Inc.
NASDAQ:RNA
Intrinsic Alpha fair value
Locked
Current Price
$6.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.